Objective To estimate hypertension's long-term cost and impact on life
expectancy. Design A 19-year individual follow-up study. Subjects wer
e categorized according to their baseline (1972) diastolic blood press
ure (DBP) level into three groups: normotensive (DBP < 95 mmHg), mildl
y hypertensive (DBP 95-104 mmHg), and severely hypertensive (DBP >104
mmHg), By using their social security identification numbers, we linke
d the subjects to a set of national registers covering hospital admiss
ions, use of major drugs, absence due to sickness, disability pensions
, and deaths. Subjects A random population sample of 10 284 men and wo
men aged 25-59 years from the provinces of Kuopio and North Karelia in
eastern Finland. Main outcome measures The numbers of years of life a
nd years of work lost, the cost of drugs and hospitalization, and the
value of productivity lost due to disability and premature mortality,
Results The difference in life expectancy between normotensive and sev
erely hypertensive men was 2.7 years, of which 2.0 years was due to ca
rdiovascular disease (CVD). Among women the corresponding differences
were 2.0 and 1,5 years, Severely hypertensive men lost 2.6 years of wo
rk more than did normotensive men, of which 1,7 years was due to CVD,
Among women the differences were 2.2 and 1.3 years. The mean undiscoun
ted total costs (USA dollars at 1992 prices) were $132 500 among normo
tensive, $146 500 among mildly hypertensive, and $219 300 among severe
ly hypertensive men, of which CVD accounted for 28, 39, and 43%, respe
ctively. More than 90% of the total costs were indirect productivity l
osses. Among women the total costs were lower for all DBP categories,
as were the shares of CVD-related costs. The proportional increase cos
ts on going from the lowest to the highest DBP category was, however,
somewhat larger among women. Conclusions On the population level, seve
re hypertension leads to considerable losses in terms of years of life
lost, years of work lost, and costs, However, the overall impact of m
ild hypertension is much more limited. J Hypertens 16:1103-1112. (C) 1
998 Lippincott-Raven Publishers.